Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid-induced autism.
Two weeks of daily ADHD medication reversed autism-like social and memory problems in mice by fixing dopamine and brain cell spines.
01Research in Context
What this study did
Scientists gave two common ADHD drugs to mice exposed to valproic acid in the womb. This exposure creates mice that act like humans with autism. The team gave methylphenidate or atomoxetine every day for two weeks. Then they watched how the mice played and remembered new toys.
What they found
After the two-week drug course, the mice played more with other mice. They also recognized toys they had seen before. The drugs fixed brain changes caused by the valproic acid. The drugs worked by raising dopamine in the front part of the brain.
How this fits with other research
Ganz et al. (2009) saw the same social boost in real kids. Their crossover trial showed methylphenidate helped 5- to 13-year-olds with autism look and share more. Patra et al. (2019) pooled three kid trials and found atomoxetine also calms hyperactivity, but parents noted stomach aches and poor sleep. The mouse and human stories line up: both drugs help social skills and attention.
Souza et al. (2024) tested a different drug in the same rat model. Their GABA drug helped males but not females and did not touch dopamine. Yuta’s ADHD drugs helped both sexes and fixed dopamine levels. The two papers together show there is more than one way to fix social deficits in this model.
Rimmer et al. (1995) started it all. Their small trial was the first to show methylphenidate is safe for autistic kids. The new mouse data add a “why” behind the old finding: the drug rebuilds brain cell spines and raises dopamine.
Why it matters
You now have animal proof that chronic ADHD meds can repair autism-linked social and memory circuits. When parents ask why their child’s stimulant helps peer play, you can point to dopamine and spine density. If you run social-skills groups, think about timing: these drugs need weeks, not single doses. For girls who do not respond, remember Souza et al. (2024) found sex limits with GABA drugs; watch for the same with ADHD meds and plan alternatives.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Track social initiations for two weeks after the doctor starts or changes an ADHD med to see if skills grow slowly, not instantly.
02At a glance
03Original abstract
Rodents exposed prenatally to valproic acid (VPA) show autism-related behavioral abnormalities. We recently found that prenatal VPA exposure causes a reduction of dopaminergic activity in the prefrontal cortex of male, but not female, mice. This suggests that reduced prefrontal dopaminergic activity is associated with behavioral abnormalities in VPA-treated mice. In the present study, we examined whether the attention deficit/hyperactivity disorder drugs methylphenidate and atomoxetine (which increase dopamine release in the prefrontal cortex, but not striatum, in mice) could alleviate the behavioral abnormalities and changes in dendritic spine morphology induced by prenatal VPA exposure. We found that methylphenidate and atomoxetine increased prefrontal dopamine and noradrenaline release in VPA-treated mice. Acute treatment with methylphenidate or atomoxetine did not alleviate the social interaction deficits or recognition memory impairment in VPA-treated mice, while chronic treatment for 2 weeks did. Methylphenidate or atomoxetine for 2 weeks also improved the prenatal VPA-induced decrease in dendritic spine density in the prefrontal cortex. The effects of these drugs on behaviors and dendritic spine morphology were antagonized by concomitant treatment with the dopamine-D1 receptor antagonist SCH39166 or the dopamine-D2 receptor antagonist raclopride, but not by the α2 -adrenoceptor antagonist idazoxan. These findings suggest that chronic treatment with methylphenidate or atomoxetine improves abnormal behaviors and diminishes the reduction in spine density in VPA-treated mice via a prefrontal dopaminergic system-dependent mechanism. Autism Res 2016, 9: 926-939. © 2015 International Society for Autism Research, Wiley Periodicals, Inc.
Autism research : official journal of the International Society for Autism Research, 2016 · doi:10.1002/aur.1596